800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

view all Clinical Trials

Overview

Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study. People can only take part if they show no improvement in lung function after standard treatment with immunosuppressant medicine. The main purpose of this study is to find out how a medicine called nerandomilast affects the lungs in people with systemic autoimmune rheumatic disease.

Clinical Trial Information

Protocol

TIRB#: 32289

Phase

3

Condition(s)

Interstitial Lung Disease (ILD)

Investigator

Gerard Criner, MD

Coordinator

Sheril George

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.

Full Title

A Double Blind, Randomised, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nerandomilast Over at Least 26 Weeks in Patients With Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases (SARD-ILD)